A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes

NCT04809220 · Completed

Last updated 2026-05-28

This clinical trial tested two different doses of the medication dulaglutide in Japanese adults with type 2 diabetes to see how it affects their blood sugar levels over 26 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 591 people

Who can join Ages 20+ · all sexes

Timeline Started 2021-04 · est. completion 2023-04

Where 44 sites · Japan

What this study is testing ClinicalTrials.gov NCT04809220 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate the efficacy and safety of 2 doses of dulaglutide in Japanese participants with type 2 diabetes. The study duration is approximately 58 weeks.

Treatments tested

Dulaglutide also known as LY2189265 Drug

Administered SC
Oral antihyperglycemics Drug

Administered orally

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Hypoglycemic Agents, Type 2 Diabetes Mellitus (T2DM)
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04809220 ↗